Key result
TEG Platelet Mapping shows ~5% analytical variation, enabling routine monitoring of highly variable ADP receptor inhibition.
Cross-Sectional (n=43)
No
The TEG Platelet Mapping assay demonstrates an analytical variation of ~5%, suggesting it may be suitable for routine monitoring of antiplatelet therapy and ADP receptor inhibition.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for TEG Platelet Mapping in antiplatelet monitoring; prospective studies needed before clinical adoption.
Bochsen et al. (2007) conducted a cross-sectional in Healthy blood donors (n=43). TEG Platelet Mapping assay was evaluated on Analytical (CVa) and inter-individual variability (CVg) of the TEG Platelet Mapping assay. The TEG Platelet Mapping assay demonstrated an analytical variation of approximately 5%, enabling routine monitoring, while revealing high inter-individual variability (26.2%) in natural ADP receptor inhibition.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: